Online inquiry

IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10721MR)

This product GTTS-WQ10721MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FCGRT gene. The antibody can be applied in Autoimmune diseases research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10721MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6380MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CSL654
GTTS-WQ2162MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ALD-518
GTTS-WQ7546MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GC-182
GTTS-WQ4605MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-986015
GTTS-WQ14620MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SC0001
GTTS-WQ8704MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ11877MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MLN-0264
GTTS-WQ2156MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ALD-518
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW